[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100560634":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":32,"locations":37,"responsibleParty":42,"collaborators":37,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":37,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":37,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":37,"overallStatus":65,"whyStopped":37,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":37},{"fullName":5,"class":6},"Children's Blood and Cancer Center at Dell Children's Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Reduced dose Ketorolac Arm A","EXPERIMENTAL","a reduced dose of Ketorolac, 15 mg\u002FmL",[13],"Drug: Ketorolac",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard of care dose Ketorolac Arm B","ACTIVE_COMPARATOR","standard of care dose of Ketorolac, 30mg\u002FmL",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Ketorolac","Randomized to a single dose of:\n\nArm A: 15 mg\u002FmL (per mL) Arm B: 30 mg\u002FmL (per mL)",[9,15],[26],"Toradol",[28],{"name":29,"affiliation":30,"role":31},"Alicia Chang, MD","Director, Comprehensive Sickle Cell Center","PRINCIPAL_INVESTIGATOR",[33,39],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},"Rhea Robinson, RN, BSN","CONTACT","512-628-1902",null,"Rmrobinson@ascension.org",{"name":40,"role":35,"phone":36,"phoneExt":37,"email":41},"Ashley Sherrod, RN, BSN","APSherrod@ascension.org",{"type":43,"investigatorFullName":37,"investigatorTitle":37,"investigatorAffiliation":37,"oldNameTitle":37,"oldOrganization":37},"SPONSOR","100560634","phase-4-ketorolac-for-acute-vaso-occlusive-crisis-in-pediatric-sickle-cell-disease-100560634",false,"NCT06579703","Ketorolac for Acute Vaso-Occlusive Crisis in Pediatric Sickle Cell Disease","Ketorolac Dosing for Acute Vaso-Occlusive Crisis in Pediatric Patients With Sickle Cell Disease","Inclusion Criteria:\n\n* Pediatric patients with sickle cell disease (any genotype) who present to DCMC Emergency department or outpatient hematology clinic with acute pain.\n\nExclusion Criteria:\n\n* Patients receiving NSAID medication \\\u003C6 hours from presentation\n* known kidney injury\n* sickle nephropathy\n* bleeding concerns\n* allergy to NSAID medication\n* chronic pain patient\n* hemodynamic instability as defined by the treating provider","ALL","1 Day","21 Years",{"count":55,"type":56},102,"ESTIMATED","INTERVENTIONAL",[59],"PHASE4","Pediatric patients who present with acute vaso-occlusive pain crisis may have equivalent pain reduction scores at lower dosing of intravenous Ketorolac compared to standard dosing of 0.5 mg\u002Fkg\u002Fdose IV (\\\u003C16yo max 15mg, \\>16yo max 30mg) x 1 dose.",[62,63,64],"Sickle Cell Disease","Sickle Cell Crisis","Veno-occlusive Disease","NOT_YET_RECRUITING","2024-08-28",{"date":68,"type":69},"2024-08-30","ACTUAL",{"date":71,"type":56},"2024-09-30",{"date":73,"type":56},"2028-02-15",{"name":5,"class":6}]